Oncompass Medicine
Private Company
Funding information not available
Overview
Oncompass Medicine is a Budapest-based precision oncology company leveraging artificial intelligence to interpret complex genomic data and recommend personalized cancer treatments. Its flagship offering is a comprehensive Precision Oncology Program, which includes consultation, molecular diagnostics planning, and treatment selection powered by its proprietary Genomate AI software. The company has established key European partnerships with diagnostic and data firms and has been recognized as a 'Future Unicorn,' positioning it at the intersection of AI, diagnostics, and clinical decision support in oncology.
Technology Platform
Genomate AI: A proprietary medical AI software system that analyzes tumor genomic data against a knowledge base of compounds, mutations, and clinical evidence to recommend personalized targeted therapy options for cancer patients.
Opportunities
Risk Factors
Competitive Landscape
Oncompass competes in the growing market of AI-powered clinical decision support (CDS) in oncology, facing competition from pure-play AI startups (e.g., Tempus, Paige.AI outside Europe), large diagnostic companies integrating AI, and electronic health record vendors. Its differentiation lies in its integrated service program and strong European partnership network.